Business Context and Reporting Period
Company: Access Pharmaceuticals, Inc. (Note: Metadata referenced "Abeona Therapeutics," but the filing text identifies the registrant as Access Pharmaceuticals, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Filing Date: May 19, 2009
Access Pharmaceuticals is an emerging biopharmaceutical company focused on nanopolymer chemistry and drug delivery technologies. The company operates with one FDA-approved product (MuGard) and a pipeline of candidates in various clinical stages. A significant event during the period was the acquisition of MacroChem Corporation on February 25, 2009, recorded under the pooling-of-interest method due to common control.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Total Revenues | $41,000 | $38,000 |
| Net Loss | $(2,089,000) | $(12,053,000) |
| Net Loss Allocable to Common Stockholders | $(2,569,000) | $(13,886,000) |
| Loss Per Share (Basic & Diluted) | $(0.24) | $(1.76) |
| Cash and Cash Equivalents (End of Period) | $2,206,000 | $1,086,000 |
| Net Cash Used in Operating Activities | $(472,000) | $(4,389,000) |
| Working Capital Deficit | $(4,014,000) | Not explicitly stated for Q1 2008 |
| Long-Term Debt | $5,500,000 | $5,500,000 |
| Accumulated Deficit | $(238,619,000) | $(236,050,000) |
Liquidity: As of March 31, 2009, the company had a net cash burn rate of approximately $165,000 per month. Management estimates capital resources are adequate to fund operations into the first quarter of 2010.
Material Changes vs. Prior Period
- Revenue: Increased slightly to $41,000 from $38,000, driven by licensing revenue ($41,000 vs. $17,000). Sponsored research income of $21,000 in 2008 ceased as the agreement was completed.
- Expenses: Total operating expenses decreased significantly to $2,000,000 from $12,084,000. This $10.1 million decrease was primarily due to a one-time non-cash in-process research and development expense of $8.9 million in Q1 2008 related to the Somanta acquisition.
- Net Loss: The net loss allocable to common stockholders decreased by $11.3 million to $2.6 million, largely reflecting the removal of the one-time acquisition charge from the prior year comparison.
- Debt Settlement: The company issued 859,172 shares of common stock to cancel approximately $859,000 of MacroChem notes and accrued interest.
Outlook, Risks, and Management Commentary
- Going Concern: The company has incurred losses since inception and has an accumulated deficit of $238.6 million. The independent auditor's report for the prior year expressed significant doubt about the company's ability to continue as a going concern. Additional financing will be required within the next twelve months.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2009. A material weakness exists regarding the lack of segregation of duties and accounting staff, as all financial reporting is performed by the CFO.
- Dividends and Defaults: The company accrued $1,371,000 in preferred stock dividends payable. Additionally, $833,000 in liquidated damages was accrued due to the failure to maintain an effective registration statement for shares issuable upon conversion of preferred stock.
- Product Pipeline:
- MuGard: Launched in Europe (Germany, Italy, UK, Greece, Nordic countries) in April 2009.
- ProLindac: Phase 2 ovarian cancer trial showed positive safety and efficacy; 66% of patients on the highest dose achieved disease stabilization.
- Pexiganan: Phase 3 candidate for diabetic foot ulcers; seeking co-development partners.
Investor Verification Checklist
- Cash Runway: Verify if the company has secured additional financing to extend operations beyond Q1 2010, given the $165,000 monthly burn rate and $2.2M cash balance.
- Debt Obligations: Confirm the status of the $5.5 million convertible note due September 13, 2011, and the $1.37 million accrued preferred dividends.
- Registration Statement: Investigate the status of the registration statement required for preferred stock conversion to determine if the $833,000 liquidated damages accrual will increase.
- Internal Controls: Assess the timeline for hiring accounting staff to remediate the material weakness in internal controls over financial reporting.
- MacroChem Integration: Review the financial impact of the MacroChem acquisition and the cancellation of its debt via stock issuance.